Stifel maintained its hold recommendation on ResMed (RMD), even as it lowered the price target to $260. Despite a recent pullback, ResMed's valuation continues to be evaluated while receiving FDA clearance for its AI-powered Smart Comfort CPAP feature. Meanwhile, Sanders Morris Harris LLC bought 4,600 shares of RMD and Neuberger Berman Group LLC along with others increased their ResMed holdings. Despite some downgrade by Baird and removal from Goldman Sachs' conviction list, ResMed's earnings are expected to grow. ResMed reported in line with expectations, highlighting the launch of a new mask platform. The recent FDA clearance for a smart comfort device at ResMed has significantly changed its investment narrative, with the company highlighting steady revenue growth and strategic innovations. Persistent strong growth and momentum favor ResMed as a long-term stock. Notably, the company also earned respect for its considerable returns over the last five years. However, ResMed's future could be impacted by the ongoing U.S. investigation into medical device imports.
Resmed RMD News Analytics from Wed, 23 Apr 2025 07:00:00 GMT to Thu, 18 Dec 2025 21:08:18 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor -2
